In recognition of “its leadership in oncology and commitment to patients,” Servier, a healthcare company committed to therapeutic progress to serve patient needs, was awarded the Patient Champion Award at Reuter’s Annual Pharma Awards USA earlier this month.
Servier is a member of the Biotechnology Innovation Organization (BIO).
A leader in oncology “committed to bringing the promise of tomorrow to the patients,” Servier has helped over “2,000 patients receive access to standard-of-care medicines… and treatments across its portfolio.” This portfolio includes the first-of-its-kind tablets approved in the U.S. “for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older.”
“Since the inception of Servier Pharmaceuticals in the U.S. in 2018, there has been an intentional effort to build the patient voice into everything we do,” said David K. Lee, CEO of Servier Pharmaceuticals.
Servier’s commitment to patients
Shirley O’Brien, who was diagnosed with AML in 2015, describes her positive relationship with the team at the company.
“Servier provides ample resources to patients about their disease, but also provides other tools that help manage life as a cancer patient that are so needed. They encourage me to tell my story and share my experience with others and continue to elevate the patient voice,” she said. Servier takes a “holistic approach,” she added, “understanding that each patient is an individual with individual needs.”
Earlier this year, Servier’s dedication to patients was recognized in PatientView’s annual survey of U.S. patient groups, ranking “26th out of a total of 45 in the survey of the reputation of pharmaceutical companies by patient organizations working with the Group” and at 7th of 30 “among patient associations that have worked with Servier in the field of oncology.”
“Our ability to excel and champion patients is built on Servier’s unique structure and programming,” said Wendy Poage, Head of the Patient Office at Servier Pharmaceuticals.
